<br />
INTERVENTIONAL<br />
CARDIOLOGY<br />
Abbott supplement • emjreviews.com<br />
INSIDE<br />
How Bioresorbable Vascular<br />
Scaffolds Can Be Beneficial for<br />
Patients in the Long-Term<br />
HOW BIORESORBABLE VASCULAR SCAFFOLDS CAN<br />
BE BENEFICIAL FOR PATIENTS IN THE LONG-TERM<br />
*Antonio Serra,1 Flavio Ribichini,2 Nick West3<br />
1. Interventional Cardiology, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain<br />
2. Department of Medicine, University of Verona, Verona, Italy<br />
3. Department of Interventional Cardiology, Papworth Hospital NHS Trust, Cambridge, UK<br />
*Correspondence to aserrap@santpau.cat<br />
Disclosure: Restricted grant from ABBOTT Vascular.<br />
Support: The publication of this article was funded by Abbott Vascular. The views and opinions expressed<br />
are tho<a title="EMJ Int Cardiol. 2016 Suppl 13 page 1" href="http://viewer.zmags.com/publication/5b48a368?page=1"> INTERVENTIONAL CARDIOLOGY Abbott supplement • em</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 2" href="http://viewer.zmags.com/publication/5b48a368?page=2"> HOW BIORESORBABLE VASCULAR SCAFFOLDS CAN BE BEN</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 3" href="http://viewer.zmags.com/publication/5b48a368?page=3"> adoption of intracoronary stents in the lat</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 4" href="http://viewer.zmags.com/publication/5b48a368?page=4"> positive remodelling, lumen gain over time, and s</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 5" href="http://viewer.zmags.com/publication/5b48a368?page=5"> A Lumen area=5.31 mm2 B Lumen area=4.51 mm2 C L</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 6" href="http://viewer.zmags.com/publication/5b48a368?page=6"> the second group (B2, n=56) underwent the same in</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 7" href="http://viewer.zmags.com/publication/5b48a368?page=7"> Cumulative frequency distribution curves (%) 100</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 8" href="http://viewer.zmags.com/publication/5b48a368?page=8"> TLF rates and individual components of cardiac de</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 9" href="http://viewer.zmags.com/publication/5b48a368?page=9"> GABI-R registry The German-Austrian-ABSORB RegIst</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 10" href="http://viewer.zmags.com/publication/5b48a368?page=10"> REPARA trial The REgistry of PAtients with B</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 11" href="http://viewer.zmags.com/publication/5b48a368?page=11"> The length of the stented segment is a predictor </a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 12" href="http://viewer.zmags.com/publication/5b48a368?page=12"> and CTO, which today are either left alone and tr</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 13" href="http://viewer.zmags.com/publication/5b48a368?page=13"> outcomes with drug-eluting stents versus bare-met</a>
<a title="EMJ Int Cardiol. 2016 Suppl 13 page 14" href="http://viewer.zmags.com/publication/5b48a368?page=14"> metallic everolimus-eluting stent for ischa</a>